new glp 1 drugs coming GLP-1 from the Gray Market GLP-1 Antagonists Increase Plan Drug

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Yet, data on their safety and clinical utility during these reproductive windows remain limited

To access our library of previously recorded activities, visit watch.houstonmethodist.org

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Advanced Metabolic Signaling Research